Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples